|
1.
|
Jaffe HL, Lichtestein L and Sutro CJ:
Pigmented villonodular synovitis, bursitis and tenosynovitis. A
discussion of the synovial and bursal equivalents of the
tenosynovial lesion commonly denoted as xanthoma, xanthogranuloma,
giant cell tumor or myeloplaxoma of the tendon sheath, with some
consideration of this tendon sheath lesion itself. Arch Pathol.
31:731–764. 1941.
|
|
2.
|
Somerhausen NS and Fletcher CD:
Diffuse-type giant cell tumor: clinicopathologic and
immunohistochemical analysis of 50 cases with extraarticular
disease. Am J Surg Pathol. 24:479–492. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Weiss SW and Goldblum JR: Enzinger and
Weiss’s Soft Tissue Tumors. Mosby; St. Louis, MO: 2001
|
|
4.
|
Myers BW and Masi AT: Pigmented
villonodular synovitis and tenosynovitis: a clinical epidemiologic
study of 166 cases and literature review. Medicine. 59:223–238.
1980. View Article : Google Scholar
|
|
5.
|
Fletcher CDM, Bridge JA, Hogendoorn PCW
and Mertens F: WHO Classification of Tumours of Soft Tissue and
Bone (Fourth edition). 2013.
|
|
6.
|
Chassaignac CME: Cancer de la gaine des
tendons. Gaz Hosp Civ Milit. 47:185–186. 1852.
|
|
7.
|
Singh R, Grewal DS and Chakravarti RN:
Experimental production of pigmented villonodular synovitis in the
knee and ankle joints of rhesus monkeys. J Pathol. 98:137–142.
1969. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sakkers RJ, de Jong D and van der Heul RO:
X-chromosome inactivation in patients who have pigmented
villonodular synovitis. J Bone Joint Surg Am. 73:1532–1536.
1991.PubMed/NCBI
|
|
9.
|
Vogrincic GS, O’Connell JX and Gilks CB:
Giant cell tumor of tendon sheath is a polyclonal cellular
proliferation. Hum Pathol. 28:815–819. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Choong PF, Willen H, Nilbert M, et al:
Pigmented villonodular synovitis. Monoclonality and metastasis - a
case for neoplastic origin? Acta Orthop Scand. 66:64–68. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Brandal P, Bjerkehagen B and Heim S:
Molecular cytogenetic characterization of tenosynovial giant cell
tumors. Neoplasia. 6:578–583. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Fletcher JA, Henkle C, Atkins L, Rosenberg
AE and Morton CC: Trisomy 5 and trisomy 7 are nonrandom aberrations
in pigmented villonodular synovitis: confirmation of trisomy 7 in
uncultured cells. Genes Chromosomes Cancer. 4:264–266. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mertens F, Orndal C, Mandahl N, et al:
Chromosome aberrations in tenosynovial giant cell tumors and
nontumorous synovial tissue. Genes Chromosomes Cancer. 6:212–217.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Nilsson M, Hoglund M, Panagopoulos I, et
al: Molecular cytogenetic mapping of recurrent chromosomal
breakpoints in tenosynovial giant cell tumors. Virchows Arch.
441:475–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sciot R, Rosai J, Dal Cin P, et al:
Analysis of 35 cases of localized and diffuse tenosynovial giant
cell tumor: a report from the Chromosomes and Morphology (CHAMP)
study group. Mod Pathol. 12:576–579. 1999.PubMed/NCBI
|
|
16.
|
Bertoni F, Unni KK, Beabout JW and Sim FH:
Malignant giant cell tumor of the tendon sheaths and joints
(malignant pigmented villonodular synovitis). Am J Surg Pathol.
21:153–163. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Layfield LJ, Meloni-Ehrig A, Liu K,
Shepard R and Harrelson JM: Malignant giant cell tumor of synovium
(malignant pigmented villonodular synovitis). Arch Pathol Lab Med.
124:1636–1641. 2000.PubMed/NCBI
|
|
18.
|
Ushijima M, Hashimoto H, Tsuneyoshi M,
Enjoji M, Miyamoto Y and Okue A: Malignant giant cell tumor of
tendon sheath. Report of a case. Acta Pathol Jpn. 35:699–709.
1985.PubMed/NCBI
|
|
19.
|
Mitelman F, Mertens F and Johansson B:
Prevalence estimates of recurrent balanced cytogenetic aberrations
and gene fusions in unselected patients with neoplastic disorders.
Genes Chromosomes Cancer. 43:350–366. 2005. View Article : Google Scholar
|
|
20.
|
West RB, Rubin BP, Miller MA, et al: A
landscape effect in tenosynovial giant-cell tumor from activation
of CSF1 expression by a translocation in a minority of tumor cells.
Proc Natl Acad Sci USA. 103:690–695. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Möller E, Mandahl N, Mertens F and
Panagopoulos I: Molecular identification of COL6A3-CSF1 fusion
transcripts in tenosynovial giant cell tumors. Genes Chromosomes
Cancer. 47:21–25. 2008.PubMed/NCBI
|
|
22.
|
Kawasaki ES and Ladner MB: Molecular
biology of macrophage colony.stimulating factor. Colony Stimulating
Factors: Molecular and Cellular Biology. Dexter TM, Garland JM and
Testa NG: Marcel Dekker; New York, NY: pp. 155–176. 1990
|
|
23.
|
Cupp JS, Miller MA, Montgomery KD, et al:
Translocation and expression of CSF1 in pigmented villonodular
synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and
other reactive synovitides. Am J Surg Pathol. 31:970–976. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ge H, Liu K, Juan T, Fang F, Newman M and
Hoeck W: Fusion Map: detecting fusion genes from next-generation
sequencing data at base-pair resolution. Bioinformatics.
27:1922–1928. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Cleynen I and Van de Ven WJ: The HMGA
proteins: a myriad of functions (Review). Int J Oncol. 32:289–305.
2008.PubMed/NCBI
|
|
26.
|
Asmann YW, Hossain A, Necela BM, et al: A
novel bioinformatics pipeline for identification and
characterization of fusion transcripts in breast cancer and normal
cell lines. Nucleic Acids Res. 39:e1002011. View Article : Google Scholar
|
|
27.
|
Madureira PA, O’Connell PA, Surette AP,
Miller VA and Waisman DM: The biochemistry and regulation of
S100A10: a multifunctional plasminogen receptor involved in
oncogenesis. J Biomed Biotechnol. 2012:3536872012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Bonafé N, Gilmore-Hebert M, Folk NL, Azodi
M, Zhou Y and Chambers SK: Glyceraldehyde-3-phosphate dehydrogenase
binds to the AU-Rich 3′ untranslated region of colony-stimulating
factor-1 (CSF-1) messenger RNA in human ovarian cancer cells:
possible role in CSF-1 posttranscriptional regulation and tumor
phenotype. Cancer Res. 65:3762–3771. 2005.
|
|
29.
|
Woo HH, Baker T, Laszlo C and Chambers SK:
Nucleolin mediates microRNA-directed CSF-1 mRNA deadenylation but
increases translation of CSF-1 mRNA. Mol Cell Proteomics.
12:1661–1677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Woo HH, Laszlo CF, Greco S and Chambers
SK: Regulation of colony stimulating factor-1 expression and
ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol
Cancer. 11:582012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zhou Y, Yi X, Stoffer JB, et al: The
multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is
both regulated and controls colony-stimulating factor-1 messenger
RNA stability in ovarian cancer. Mol Cancer Res. 6:1375–1384. 2008.
View Article : Google Scholar
|
|
32.
|
Bakheet T, Frevel M, Williams BR, Greer W
and Khabar KS: ARED: human AU-rich element-containing mRNA database
reveals an unexpectedly diverse functional repertoire of encoded
proteins. Nucleic Acids Res. 29:246–254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Dewar AL, Cambareri AC, Zannettino AC, et
al: Macrophage colony-stimulating factor receptor c-fms is a novel
target of imatinib. Blood. 105:3127–3132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Blay JY, El Sayadi H, Thiesse P, Garret J
and Ray-Coquard I: Complete response to imatinib in relapsing
pigmented villonodular synovitis/tenosynovial giant cell tumor
(PVNS/TGCT). Ann Oncol. 19:821–822. 2008. View Article : Google Scholar
|
|
35.
|
Cassier PA, Gelderblom H, Stacchiotti S,
et al: Efficacy of imatinib mesylate for the treatment of locally
advanced and/or metastatic tenosynovial giant cell tumor/pigmented
villonodular synovitis. Cancer. 118:1649–1655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Stacchiotti S, Crippa F, Messina A, et al:
Response to imatinib in villonodular pigmented synovitis (PVNS)
resistant to nilotinib. Clin Sarcoma Res. 3:82013. View Article : Google Scholar : PubMed/NCBI
|
